In conclusion, our study is the first to explore the impact of GPR related gene signatures on the diagnosis, prediction, and immunotherapy of BLCA, providing reference for personalized immunotherapy of BLCA patients. This evidence concerns the gene ALDH18A1 and bladder transitional cell carcinoma.